

TARGETED GENETICS CORP /WA/
Form 8-K
June 04, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **June 4, 2007**

Targeted Genetics Corporation

(Exact name of registrant as specified in its charter)

<u>Washington</u> (State or other jurisdiction of incorporation)	<u>0-23930</u> (Commission File Number)	<u>91-1549568</u> (IRS Employer Identification No.)
-------------------------------------------------------------------------------	------------------------------------------------------	------------------------------------------------------------------

<u>1100 Olive Way, Suite 100, Seattle, Washington</u> (Address of principal executive offices)	<u>98101</u> (Zip Code)
----------------------------------------------------------------------------------------------------------	-----------------------------------

Registrant's telephone number, including area code **(206) 623-7612**

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On June 4, 2007, Targeted Genetics Corporation announced that it had reported additional data from the dose escalation arm of the ongoing Phase I/II clinical study of tgAAC94 in patients with inflammatory arthritis. A copy of the press release announcing this data and describing the Phase I/II trial is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibits.

99.1 Press Release of Targeted Genetics Corporation dated June 4, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Targeted Genetics Corporation

By: /s/ David J. Poston

David J. Poston
Vice President and
Chief Financial Officer

Dated: June 4, 2007

INDEX TO EXHIBITS

**Exhibit
Number Description**

99.1 Press Release of Targeted Genetics Corporation dated June 4, 2007
